MacroGenics, Inc. (MGNX): Price and Financial Metrics
GET POWR RATINGS... FREE!
MGNX POWR Grades
- MGNX scores best on the Value dimension, with a Value rank ahead of 73.28% of US stocks.
- MGNX's strongest trending metric is Momentum; it's been moving down over the last 29.7142857142857 weeks.
- MGNX's current lowest rank is in the Momentum metric (where it is better than 11.47% of US stocks).
MGNX Stock Summary
- Of note is the ratio of Macrogenics Inc's sales and general administrative expense to its total operating expenses; just 8.69% of US stocks have a lower such ratio.
- MGNX's price/sales ratio is 16.83; that's higher than the P/S ratio of 88.99% of US stocks.
- Revenue growth over the past 12 months for Macrogenics Inc comes in at 58.46%, a number that bests 90.33% of the US stocks we're tracking.
- If you're looking for stocks that are quantitatively similar to Macrogenics Inc, a group of peers worth examining would be SPRO, STRO, CERC, ALKS, and IDYA.
- MGNX's SEC filings can be seen here. And to visit Macrogenics Inc's official web site, go to www.macrogenics.com.
MGNX Stock Price Chart Interactive Chart >
MGNX Price/Volume Stats
|Current price||$30.95||52-week high||$36.48|
|Prev. close||$30.30||52-week low||$18.16|
|Day high||$31.31||Avg. volume||763,763|
|50-day MA||$31.53||Dividend yield||N/A|
|200-day MA||$25.73||Market Cap||1.86B|
MacroGenics, Inc. (MGNX) Company Bio
Macrogenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases. The company was founded in 2000 and is based in Rockville, Maryland.
MGNX Latest News Stream
|Loading, please wait...|
MGNX Latest Social Stream
View Full MGNX Social Stream
Latest MGNX News From Around the Web
Below are the latest news stories about Macrogenics Inc that investors may wish to consider to help them evaluate MGNX as an investment opportunity.
The decent performance at MacroGenics, Inc. ( NASDAQ:MGNX ) recently will please most shareholders as they go into the...
MacroGenics, Inc. (MGNX) Q1 2021 Earnings Conference Call April 29, 2021 16:30 ET Company Participants Anna Krassowska - Investor Relations Scott Koenig - President & Chief Executive Officer Jim Karrels - Senior Vice President & Chief Financial Officer Conference Call Participants Jonathan Chang - SVB Leerink Peter Lawson - Barclays...
Good afternoon, we will begin the MacroGenics 2021 first-quarter corporate progress and financial results conference call in just a moment. At this point, I will turn the call over to Jim Karrels, senior vice president, chief financial officer of MacroGenics. Good afternoon and welcome to MacroGenics'ss conference call to discuss our first-quarter 2021 financial and operational results.
The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 28) Axonics, Inc. (NASDAQ: AXNX ) Boston Scientific Corporation (NYSE: BSX ) (reacted to first-quarter results) Celcuity Inc. (NASDAQ: CELC ) Celldex Therapeutics, Inc. (NASDAQ: CLDX) Galectin Therapeutics Inc. (NASDAQ: GALT ) Horizon Therapeutics Public Limited Company (NASDAQ: HZNP ) Insulet Corporation (NASDAQ: PODD ) Integra LifeSciences Holdings Corporation (NASDAQ: IART ) (announced first-quarter results) Lantheus Holdings, Inc. (NASDAQ: LNTH ) MacroGenics, Inc. (NASDAQ: MGNX ) NuVasive, Inc. (NASDAQ: NUVA) PRA Health Sciences, Inc. (NASDAQ: PRAH ) ShockWave Medical, Inc. (NASDAQ: SWAV ) Verastem, Inc. (NASDAQ: VSTM ) Down In The Dumps (Bi...
Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 900 active prominent money managers and analyze their quarterly 13F filings. The stocks that are heavily bought by hedge funds historically outperformed the market, though there is no shortage of high profile […]
MGNX Price Returns